The association of ranitidine and sucralfate in the short-term treatment of duodenal ulcers, as compared to other forms of treatment

Int J Tissue React. 1984;6(2):189-93.

Abstract

Results of the treatment of duodenal ulcer with ranitidine (150 mg X 2/die) and sucralfate (1 gr X 2/die) have been compared with other common schemes of therapy. Administration of the drugs was carried out for 8 weeks, and the evolution of the ulcer lesion was followed with endoscopic controls at the beginning and end of the treatment. Ulcer healing occurred in 92% of 25 patients, as compared with 83,3% of 30 cases treated with ranitidine only; 80% of 30 cases with cimetidine 1 g/day; 80% of 20 cases with cimetidine 800 mg/b.i.d.; 75% of 20 cases with sucralfate 3 g/day; 73,3% of 30 patients with pirenzepine 150 mg/day; 60% of 20 cases with sulglycotide 0.5-1 g/day; and 50% of 40 ulcerous patients treated with placebo. From these results it is concluded that the association of sucralfate with an H2-antagonist improves the possibility of short-term healing of duodenal ulcer.

Publication types

  • Clinical Trial
  • Comparative Study
  • Controlled Clinical Trial

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aluminum / administration & dosage*
  • Anti-Ulcer Agents / administration & dosage*
  • Drug Therapy, Combination
  • Duodenal Ulcer / drug therapy*
  • Female
  • Humans
  • Male
  • Middle Aged
  • Ranitidine / administration & dosage*
  • Sucralfate

Substances

  • Anti-Ulcer Agents
  • Sucralfate
  • Ranitidine
  • Aluminum